Steven Leonard Chapman Sells 6,111 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA - Get Free Report) CEO Steven Leonard Chapman sold 6,111 shares of the stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $157.10, for a total value of $960,038.10. Following the completion of the transaction, the chief executive officer now directly owns 179,071 shares in the company, valued at $28,132,054.10. This trade represents a 3.30% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Steven Leonard Chapman also recently made the following trade(s):

• On Thursday, May 1st, Steven Leonard Chapman sold 6,980 shares of Natera stock. The shares were sold at an average price of $150.10, for a total value of $1,047,698.00.
• On Monday, April 28th, Steven Leonard Chapman sold 6,203 shares of Natera stock. The shares were sold at an average price of $152.18, for a total value of $943,972.54.
• On Monday, April 21st, Steven Leonard Chapman sold 1,664 shares of Natera stock. The stock was sold at an average price of $145.55, for a total value of $242,195.20.
• On Monday, March 31st, Steven Leonard Chapman sold 9,563 shares of Natera stock. The stock was sold at an average price of $138.41, for a total value of $1,323,614.83.
• On Monday, March 17th, Steven Leonard Chapman sold 6,702 shares of Natera stock. The stock was sold at an average price of $146.03, for a total value of $978,693.06.

Natera Stock Performance

NASDAQ:NTRA traded down $1.75 during mid-day trading on Friday, reaching $163.76. The stock had a trading volume of 1,016,903 shares, compared to its average volume of 1,409,610. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The firm has a market capitalization of $22.36 billion, a price-to-earnings ratio of -93.05 and a beta of 1.74. Natera, Inc. has a twelve month low of $92.14 and a twelve month high of $183.00. The business has a 50 day simple moving average of $151.77 and a 200 day simple moving average of $158.53.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The medical research company reported ($0.50) EPS for the quarter, beating analysts' consensus estimates of ($0.59) by $0.09. The firm had revenue of $501.83 million during the quarter, compared to the consensus estimate of $446.68 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The firm's revenue was up 36.5% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.56) earnings per share. On average, analysts expect that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Natera

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Blue Trust Inc. grew its stake in Natera by 104.3% in the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock worth $30,000 after acquiring an additional 97 shares during the period. Caprock Group LLC purchased a new stake in shares of Natera during the 4th quarter valued at $213,000. Chicago Partners Investment Group LLC purchased a new stake in shares of Natera during the 4th quarter valued at $297,000. Hodges Capital Management Inc. purchased a new stake in Natera during the 4th quarter worth $372,000. Finally, GDS Wealth Management boosted its position in Natera by 245.0% during the 4th quarter. GDS Wealth Management now owns 12,463 shares of the medical research company's stock worth $1,973,000 after purchasing an additional 8,851 shares during the period. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have issued reports on NTRA shares. BTIG Research reaffirmed a "buy" rating on shares of Natera in a report on Friday, February 28th. Piper Sandler raised their price objective on Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a report on Thursday, May 15th. Royal Bank of Canada started coverage on Natera in a report on Thursday, March 13th. They set an "outperform" rating and a $251.00 price objective on the stock. Canaccord Genuity Group reaffirmed a "buy" rating and set a $180.00 price objective on shares of Natera in a report on Wednesday, February 26th. Finally, Wall Street Zen lowered Natera from a "hold" rating to a "sell" rating in a report on Saturday, May 17th. One equities research analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $184.63.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.